Vijaya Kumar Sengodan Gurusamy, Mishra Dina Nath
Department of Pharmaceutical Sciences, Guru Jambheshwar University, Hisar-125001, Haryana, India.
Chem Pharm Bull (Tokyo). 2006 Aug;54(8):1102-6. doi: 10.1248/cpb.54.1102.
In the present study, the solubilizing and amorphizing properties of Valdecoxib (a poorly water soluble anti inflammatory drug) with low molecular weight chitosan (a polymer), have been investigated. Binary systems of varying drug/polymer ratios were prepared using different techniques (physical mixing, co-grinding, kneading) and were tested for dissolution. Drug carrier interactions were investigated in both the liquid and solid state, by phase solubility analysis, differential scanning calorimetry, powder X-ray diffractrometry, FT-IR spectroscopy and scanning electron microscopy. The solubility of the drug increased with increasing polymer concentration showing A(N) type phase solubility diagram. Differential scanning calorimetry, powder X-ray diffractrometry and scanning electron microscopic studies of binary systems suggested generation of amorphous form of drug (in kneading and co ground mixtures). IR spectroscopy revealed the presence of hydrogen bonding in kneading and co ground mixtures. Drug dissolution was improved with increasing the polymer concentration in the mixture (Kneaded>co ground>physical mixture), which was attributed to the amorphonization and/or decreased drug crystallinity, size and polymer wetting effect. Enhanced dissolution combined with its direct compression feasibility and anti ulcerogenic action results in low molecular weight chitosan for developing fast release oral solid dosage forms of valdecoxib.
在本研究中,已对伐地昔布(一种水溶性差的抗炎药物)与低分子量壳聚糖(一种聚合物)的增溶和非晶化性质进行了研究。使用不同技术(物理混合、共研磨、捏合)制备了不同药物/聚合物比例的二元体系,并对其进行了溶出度测试。通过相溶解度分析、差示扫描量热法、粉末X射线衍射法、傅里叶变换红外光谱法和扫描电子显微镜,对药物载体在液态和固态下的相互作用进行了研究。药物的溶解度随聚合物浓度的增加而增加,呈现A(N)型相溶解度图。二元体系的差示扫描量热法、粉末X射线衍射法和扫描电子显微镜研究表明,药物生成了非晶态形式(在捏合和共研磨混合物中)。红外光谱显示捏合和共研磨混合物中存在氢键。随着混合物中聚合物浓度的增加,药物溶出度得到改善(捏合>共研磨>物理混合物),这归因于非晶化和/或药物结晶度、粒径的降低以及聚合物的润湿性作用。溶出度的提高及其直接压片的可行性和抗溃疡作用,使得低分子量壳聚糖可用于开发伐地昔布的速释口服固体剂型。